Adherence to Adjuvant Endocrine Therapy in Christchurch Women with Early Breast Cancer

Robinson, Bridget A.; Dijkstra, B.; Davey, Valerie; Tomlinson, Stephen; Frampton, Christopher

doi:10.1016/j.clon.2017.10.015

Cited by 27 publications

(37 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Of the 769 patients who took the medication consistently, 50.2% reported side effects, and 69.9% of patients with low compliance had at least one side effect. The rate of side effects in this study was similar to a New Zealand study in which 52.5% of patients had side effects and 30.9% of patients stopped taking drugs due to side effects 22 . A survey of women in Detroit and Los Angeles who started endocrine therapy showed that of those who stopped early, 40% stopped for side effects and 25% cited worry about risks 29 .…”

Section: Discussionsupporting

confidence: 80%

“…The nonpersistence rate of 13.4% in our study was similar to that of Japan (12%) 20 . Our discontinuation rate of 22.6% at the fifth year is lower than that of most previous reports, which estimated discontinuation rates ranging from 31% to 73% 11‐12,21,22 . Higher than an USA study of 538 women with 18% non‐persistent at 5 years, 23 similar to the NSABP B‐14 trial, whose discontinuation rates were 23% in both the placebo group and the experimental group for 60 months 24 .…”

Section: Discussionsupporting

confidence: 71%

See 1 more Smart Citation

Adherence status to Adjuvant Endocrine Therapy in Chinese Women with Early Breast Cancer and its influencing factors: A cross‐sectional survey

Jin

Zhang

et al. 2020

Cancer Medicine

View full text Add to dashboard Cite

Objective: Despite the proven benefits of adjuvant endocrine therapy, adherence to oral endocrine therapy in breast cancer treatment is a substantial problem. The aim of this study was to assess adherence to adjuvant endocrine therapy by women in China for the first 5 years, and to identify its influencing factors. Methods: Stratified sampling method was adopted to select 1875 cases of breast cancer patients for cross-sectional telephone follow-up. Compliance to medications was assessed using the Morisky Medication Adherence Scale. Status of endocrine therapy was assessed using nine additional questions. Binomial regression was used when assessing the factors associated with persistence, multinomial regression models were used to assess factors associated with compliance. Results: Of 888 patients who started adjuvant endocrine therapy, 769(86.6%) persisted and 119 (13.4%) discontinued. 760 patients who completed Morisky Medication Adherence Scale, the compliance was 7.4% low, 42% medium, and 50.6% high. The type of medication, duration of medication and side effects had an impact both on persistence and compliance. Age, history of radiotherapy and caregivers only had an impact on persistence. Conclusions: Medication adherence was affected by many factors. Special attention and interventions should be given to women taking tamoxifen in the 2nd to 3rd year of medication, and aromatase inhibitors in the 1st to 2nd year. Further prospective design studies are needed to explore effective measures to improve medication adherence of women with breast cancer treated by endocrine therapy. K E Y W O R D Sadherence, breast cancer, compliance, endocrine therapy, oncology, persistence

show abstract

Section: Discussionsupporting

confidence: 80%

Section: Discussionsupporting

confidence: 71%

Adherence status to Adjuvant Endocrine Therapy in Chinese Women with Early Breast Cancer and its influencing factors: A cross‐sectional survey

Jin

Zhang

et al. 2020

Cancer Medicine

View full text Add to dashboard Cite

show abstract

“…Avaliação dos pacientes quanto a adesão ao tratamento com TMX e sua associação com o número de medicamentos, número de reações adversas e tempo de uso do TMX. de efeitos adversos e a baixa tolerabilidade com terapia 15 . No Brasil, verificou-se que o esquecimento como principal motivo entre 27 participantes.…”

Section: Discussionunclassified

“…3 A associação entre tempo de tratamento e redução da adesão também foi observada em estudo realizado na Nova Zelândia com 1.230 mulheres, na avaliação após um ano de tratamento com tamoxifeno 90% eram aderentes, com dois anos 84%, aos três anos 81%, aos quatro anos 76%, e aos cinco anos apenas 50%. 15 Esses achados da literatura demonstram que quanto mais prolongado é o tempo de tratamento, maior é o risco das pacientes desistirem do seu tratamento. 15 Também pode estar associado a gravidade da doença, presença de outras doenças associadas e até mesmo aos efeitos adversos, produzindo diferentes respostas ao tratamento.…”

Section: Discussionunclassified

“…15 Esses achados da literatura demonstram que quanto mais prolongado é o tempo de tratamento, maior é o risco das pacientes desistirem do seu tratamento. 15 Também pode estar associado a gravidade da doença, presença de outras doenças associadas e até mesmo aos efeitos adversos, produzindo diferentes respostas ao tratamento. 6 No presente estudo não se observou associação entre o tempo de tratamento e a adesão, no entanto, infere-se que a média do tempo de uso foi superior a um ano e não foi realizado o acompanhamento dessas pacientes até o final do tratamento, o que dificulta essa análise e apresenta-se como limitação do presente estudo.…”

Section: Discussionunclassified

See 1 more Smart Citation

Tamoxifen treatment adherence assessment by women with breast cancer

Rangel

Colet

Bandeira

et al. 2020

Rev Epidemiol Control Infect

View full text Add to dashboard Cite

Justification and objectives: oral antineoplastic therapy has advantages compared to other therapies for the treatment of cancer, as it is administered at home, in a simple and fast way. However, this therapy increases patients’ responsibility for their treatment, and compliance is critical to its effectiveness. Few studies are evident regarding pharmacotherapeutic follow-up in oral antineoplastic therapy. In this context, this study seeks to assess adherence to tamoxifen treatment in women with breast cancer, before and after pharmacotherapeutic follow-up. Methods: this is a randomized, quantitative clinical study. Data collection was carried out for six months. Random randomization was divided into a control group and a follow-up group, with the follow-up subdivided into before and after follow-up. The follow-up group received individual pharmaceutical interventions monthly. Adherence was assessed by The Brief Medication Questionnaire, Brazilian version and drug-related problems as to necessity, effectiveness, and safety. Results: after pharmaceutical follow-p, a difference was observed between the follow-up group and the control group regarding physical activity (p=0.043), treatment adherence (p=0.006), reduction of side effects (p=0.003) and associated diseases (p=0.002). The most frequent drug-related problems were safety and adherence, for which 54 pharmaceutical interventions were performed. The side effects described by patients mainly affected the genital system and gastrointestinal tract. Conclusion: it was evident that pharmacotherapeutic follow-up effectively contributed to adherence to treatment with tamoxifen and the pharmaceutical interventions performed contributed to prevention and reduction of drug-related problems.

show abstract

Using data mining technology to predict medication‐taking behaviour in women with breast cancer: A retrospective study

2021

View full text Add to dashboard Cite

Breast cancer is one of the most common cancers among women worldwide (World Health Organization, 2019). Approximately, 2.1 million new cases of breast cancer were diagnosed in 2018, and nearly 627,000 deaths were attributed to the disease (WHO, 2019).Approximately, 75% of breast cancers are oestrogen receptorpositive (ER+) (Moon et al., 2017). Most ER + people with breast cancer are prescribed adjuvant hormonal therapy (AHT), which blocks the effects of oestrogen to inhibit breast cancer cell growth (Moon et al., 2017). AHT choices of tamoxifen or aromatase inhibitors (AIs) depend on the menopausal status of the patient (Pourcelot et al., 2018). AHT for a period of 5-10 years is a standard therapy for obtaining the maximum benefits in breast cancer treatment

show abstract

Adherence to Adjuvant Endocrine Therapy in Christchurch Women with Early Breast Cancer

Cited by 27 publications

References 23 publications

Adherence status to Adjuvant Endocrine Therapy in Chinese Women with Early Breast Cancer and its influencing factors: A cross‐sectional survey

Adherence status to Adjuvant Endocrine Therapy in Chinese Women with Early Breast Cancer and its influencing factors: A cross‐sectional survey

Tamoxifen treatment adherence assessment by women with breast cancer

Using data mining technology to predict medication‐taking behaviour in women with breast cancer: A retrospective study

Contact Info

Product

Resources

About